| 000 | 01646 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517130038.0 | ||
| 264 | 0 | _c20171215 | |
| 008 | 201712s 0 0 eng d | ||
| 022 | _a1873-2518 | ||
| 024 | 7 |
_a10.1016/j.vaccine.2016.10.073 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPan-Ngum, Wirichada | |
| 245 | 0 | 0 |
_aPredicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach. _h[electronic resource] |
| 260 |
_bVaccine _c01 2017 |
||
| 300 |
_a403-409 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 |
_aDisease Transmission, Infectious _xprevention & control |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 |
_aKenya _xepidemiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aModels, Theoretical |
| 650 | 0 | 4 |
_aRespiratory Syncytial Virus Infections _xepidemiology |
| 650 | 0 | 4 |
_aRespiratory Syncytial Virus Vaccines _xadministration & dosage |
| 650 | 0 | 4 |
_aRespiratory Syncytial Viruses _ximmunology |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKinyanjui, Timothy | |
| 700 | 1 | _aKiti, Moses | |
| 700 | 1 | _aTaylor, Sylvia | |
| 700 | 1 | _aToussaint, Jean-François | |
| 700 | 1 | _aSaralamba, Sompob | |
| 700 | 1 | _aVan Effelterre, Thierry | |
| 700 | 1 | _aNokes, D James | |
| 700 | 1 | _aWhite, Lisa J | |
| 773 | 0 |
_tVaccine _gvol. 35 _gno. 2 _gp. 403-409 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.vaccine.2016.10.073 _zAvailable from publisher's website |
| 999 |
_c26664052 _d26664052 |
||